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Introduction. Nonsurgical management of patients with desmoid-type ﬁbromatosis (DF) is increasing. .is study tries to provide
insight on type, usage, and outcome of ﬁrst-line nonsurgical management strategies. Patients and Methods. From the Dutch
Pathology Registry (PALGA), patients with extra-abdominal or trunk/abdominal wall DF, diagnosed between 1993 and 2013,
were identiﬁed. First-line treatment was analyzed. Best response (BR) using RECIST criteria from start of treatment/surveillance
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until change of treatment or last follow-up was analyzed. Results. Ninety-one of the 1141 identiﬁed patients had ﬁrst-line
nonsurgical management. .e percentage of patients treated nonsurgically increased from 0.6% in 1993–1998 to 12.8% in
2009–2013. .irty-seven patients had surveillance (41%), 35 radiotherapy (38%), and 19 systemic treatment (21%). BR for
surveillance was complete response (CR) in 2/37, partial response (PR) in 4/37, stable disease (SD) in 21/37, progressive disease
(PD) in 5/37, and unknown in 5/37 patients. BR for radiotherapy was CR in 4/35, PR in 11/35, SD in 16/35, and unknown in 4/35.
BR for systemic treatment was CR in 1/19, PR in 1/19, SD in 10/19, PD in 2/19, and unknown in 5/19. Totally, 91% of patients did
not progress. Discussion. Given the low percentage (9%) of PD of nonsurgical management, these data can be used in shared
decision making with the patient regarding optimal treatment.
1. Introduction
Desmoid-type ﬁbromatosis (DF or aggressive ﬁbromatosis)
is an intermediate grade soft tissue tumor that does not
metastasize, but can be locally aggressive [1]. For long,
surgery has been the primary treatment for resectable tu-
mors, with or without additional radiotherapy. Currently,
a more conservative approach is applied based on reports of
disease stabilization and spontaneous regression, and on
documented progression after surgery as radical resection
may be diﬃcult to achieve [2, 3]. An epidemiological study
conducted in extra-abdominal and trunk/abdominal wall
DF patients in the Netherlands reported an increase in the
use of nonsurgical modalities over the past decade [4].
A European consensus on the management of DF has
recently been published, advocating active surveillance as
the initial treatment modality, with systemic treatment,
surgery or radiotherapy in case of tumor progression [5].
Despite a trend towards conservative treatment, knowledge
on the outcome of diﬀerent management modalities as ﬁrst-
line treatment is limited.
Studies on radiotherapy have described disease stabiliza-
tion and tumor regression [6–8]. .e literature on systemic
treatment is limited, with a variety of treatment regimes, often
applied at diﬀerent stages of disease presentation [9–18].
Active surveillance is currently being investigated in a pro-
spective setting by three diﬀerent groups; a French group
(NCT01801176), an Italian group (NCT02547831), and
a Dutch group (NTR4714) [19]. Nonsurgical management of
patients with DF is increasing. Population-based studies are
needed to gain insight into the actual implementation of
nonsurgical treatment in daily practice. .is retrospective
study provides insight into the application and outcome of all
ﬁrst-line treatment modalities in a nationwide cohort of DF
patients during routine clinical care.
2. Patients and Methods
From the PALGA, the nationwide network and registry of
histopathology and cytopathology in the Netherlands, patients
diagnosed between 1-1-1993 and 31-12-2013 having extra-
abdominal or trunk/abdominal wall DF were identiﬁed. .e
PALGA database contains encoded excerpts of all nationwide
pathology examinations obtained by diagnostic procedure,
including tissue biopsy or resection, since 1971 in selected
laboratories and expanded to nationwide inclusion in 1991
[20]. Due to incomplete data registration, patients with disease
presentation before 1993 were excluded. Excerpts contained
standardized information: an encrypted patient identiﬁcation,
date of pathology report, age and gender of the patient, and the
conclusion of the pathology reports. Reports were scored
as biopsy, resection, or re-resection. Patients with diagnostic
biopsy of DF without excision specimens within 6 months of
biopsy were selected. Patients with excision specimens within
6 months of biopsy were considered to have initial surgical
treatment. Exclusion criteria were intra-abdominal DF, re-
current disease at presentation, uncertain diagnosis, and initial
surgical treatment.
Hospitals with more than 10 patients were contacted for
information. Data collection was performed in seven tertiary
referral centers, as most patients were referred to these
centers after diagnosis. In addition to the PALGA database,
center-based registrations were searched for patients. For all
selected patients in these seven centers medical records were
reviewed. From the excerpts and the medical records, data
were collected on age, gender, year of diagnosis, localization,
size, nuclear beta-catenin, CTNNB1 mutations, APC mu-
tations, treatment modalities, date of start of treatment,
response to treatment, and toxicities. Only the ﬁrst-line of
treatment was documented.
Tumor localization was categorized as head/neck, trunk
(including thoracic wall, breast, and back), abdominal wall,
extremity, or groin. Type of systemic treatment was cate-
gorized as nonsteroidal anti-inﬂammatory drug (NSAID),
antihormonal (HT), chemotherapy (ChT), or tyrosine ki-
nase inhibitors (TKI).
Reports from all available imaging studies were reviewed.
Best response to treatment was classiﬁed using RECIST 1.1 as
complete response (CR), partial response (PR) in case of≥30% decrease of the largest diameter , stable disease (SD), or
progressive disease (PD) in case of ≥20% increase of the largest
diameter based on reported measurements [21]. Date of the
start of treatment was deﬁned as the date of visit with the
physician in which the treatment modality was initiated or
date of start of radiotherapy. In most patients, active sur-
veillance was initiated within 3 weeks after diagnosis. Results
are shown as best response and time to progression (TTP).
TTP was deﬁned as the period from start of treatment to
radiological PD as classiﬁed by RECIST 1.1. Follow-up period
for each treatment was documented as time of start treatment
or active surveillance until change of treatment or last docu-
mented follow-up visit, whichever came ﬁrst.
Late toxicity after radiotherapy was retrospectively
scored using RTOG-EORTC criteria [22].
Statistical analysis was performed using IBM SPSS Sta-
tistics 21. Continuous variables are shown as median with
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interquartile range (IQR), and categorical variables as numbers
with percentages.
3. Results
e PALGA search covering the period between 1-1-1993 and
31-12-2013, identi­ed 1134 patients with extra-abdominal and
trunk/abdominal wall DF. Patients were selected using in-
clusion and exclusion criteria (Figure 1). Of these 1134
patients, 277 ful­lled the inclusion criteria for our study and
181 of these patients were treated in one of the seven hospitals
selected for our study. eir ­les were reviewed for details
on tumor characteristics and treatment modalities. After chart
review, 90 additional patients were excluded because the
chart review revealed additional information not available in
the pathology report. Centre-based registrations provided
data on additional patients (diagnosed in 2014). In total, 91
patients were included for further analysis based on in-
clusion and exclusion criteria. Baseline characteristics are
listed in Table 1. Details on beta-catenin (CTNNB1) and
APC gene mutation status were reported sporadically. To
our knowledge, 6 patients with APC gene mutation were
included. Due to the scarce data, these factors were not
included in further analyses.
Based on initial management, patients were divided in 3
groups: active surveillance, radiotherapy, and systemic treat-
ment. Outcomes for each group are listed in Table 2. Median
follow-up for active surveillance, radiotherapy, and systemic
treatment was 16months (IQR 7–31), 44months (IQR 24–62),
and 5 months (IQR 2–12), respectively.
ere is a clear increase in the use of nonsurgical man-
agement over the years, from 0.6% in 1993–1998 up to 12.8%
PALGA database of patients with new
diagnosis of extra-abdominal DF
(n = 1134) 
Requested identification by PALGA
(n = 277)
Exclusion on patients with excision <6
months of diagnosis or patients with
primary excision (n = 857)
All laboratories were contacted for
further identification based on local
pathology numbers.
277 excerpts were linked to 328
pathology numbers in 50 laboratories
(51 double identifications)
(n = 328)
Response from 24 laboratories,
responsible for 219 excerpts (including
unknown number of doubles).
(n = 219)
Requested identification by PALGA to 
link excerpt number to pathology
number and laboratory
181 patients identified and available for
file review 











Centers with >10 pathology numbers
were contacted for patient identification
and file retrieval (n = 186) 
11 centers, 8 willing to cooperate.
(n = 152) 
Center-based databases were
available for additional inclusion




Figure 1: CONSORT diagram of patient selection.
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in 2009–2013 (Table 3). Table 3 also presents data of 7 ad-
ditional patients diagnosed in 2014, which were found during
chart review.
3.1. Active Surveillance. .irty-seven patients had active
surveillance after diagnosis. Tumor localization was as follows:
3 patients with head/neck tumors, 13 patients with truncal
tumors, 17 patients with abdominal wall tumors, and 4 pa-
tients with extremity tumors.
Best response during that period was spontaneous CR for
2 patients (5%), PR for 4 patients (11%), SD for 21 patients
(57%), and PD for 5 patients (14%). For 5 patients, images
required for RECIST were not available. CR was documented
after 12 and 17 months, and PR was documented after 5, 10,
12, and 36 months. During the follow-up period, 13 patients
had progressive disease with a median TTP of 7.3 months
(IQR 4.1–11.9). In total, 22 patients (63%) were still under
active surveillance at the date of last follow-up after
a median of 16 months, including all patients with CR or
Table 1: Baseline characteristics.
All patients ActiveSurveillance Radiotherapy
Systemic
treatment
N % N % N % N %
Gender
Male 30 33 9 24.3 12 34.3 9 47.4
Female 61 67 28 75.7 23 65.7 10 52.6
Age (years)
Median (IQR) 39 (33.1–52.2) 36 (31.2–51.6) 43.6 (39.4–52.4) 34.8 (23.3–46.3)
Localization
Head/neck 9 9.9 3 8.1 6 17.1 — —
.orax/back 35 38.5 13 35.1 13 37.1 9 47.4
Abdominal wall 25 27.5 17 45.9 1 2.9 7 36.8
Extremity 21 23.1 4 10.8 15 42.9 2 10.5
Others∗ 1 1.1 — — — — 1 5.3
Size<5 cm 25 27.5 16 43.2 7 20.0 2 10.5
5–10 cm 48 52.7 18 48.6 19 54.3 11 57.9>10 cm 15 16.5 2 5.4 8 22.9 5 26.3
Missing data 3 3.3 1 2.7 1 2.9 1 5.3
Beta-catenin (nuclear)
Positive 56 61.5 28 75.7 16 45.7 12 63.2
Negative 10 11 3 8.1 6 17.1 1 5.3
Unknown 25 27.5 6 16.2 13 37.1 6 31.6
N� number of patients; cm� centimeter; IQR� interquartile range; ∗groin.
Table 2: Outcome of nonsurgical treatment, using best response according to RECIST.
CR PR SD PD Unknown Total
N % N % N % N % N % N
Active surveillance 2 5.4% 4 10.8% 21 56.8% 5 13.5% 5 13.5% 37
Radiotherapy 4 11.4% 11 31.4% 16 45.7% 0 0% 4 11.4% 35
Systemic treatment 1 5.3% 1 5.3% 10 52.6% 2 10.5% 5 26.3% 19
N� number of patients; CR� complete response; PR� partial response; SD� stable disease; PD� progressive disease.
Table 3: First-line nonsurgical treatment per 5-year time period.
1993–1998 1999–2003 2004–2008 2009–2013 2014 Total
N N N N N N
PALGA registration [4] 180 185 331 438 1134
First-line treatment 1 5 22 56 7 91
Stratiﬁed treatment
Active surveillance 0 0 5 26 6 37
Radiotherapy 0 1 13 20 1 35
Systemic treatment 1 4 4 10 0 19
Percentage∗ 0.6% 2.7% 6.6% 12.8% 8.0%
N� number of patients. ∗Percentage of nonsurgical treatment compared to overall diagnoses as documented in the PALGA registration.
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PR (median duration of active surveillance for patients
with CR and PR was 22 months; IQR 13–46). Of the 21
patients with SD as best outcome, 3 ended active sur-
veillance due to complaints related to the tumor without
actual progression and 5 patients ended due to progression
(<20%). .irteen patients with SD continued active sur-
veillance till end of follow-up. Of the 5 patients with PD, 1
patient continued active surveillance. Two patients with
unknown outcome continued active surveillance till end of
follow-up.
3.2. Radiotherapy. Initial treatment was radiotherapy for 35
patients. Tumor localization was categorized as follows: 6
patients with head/neck tumors, 13 patients with truncal
tumors, 1 patient with abdominal wall tumor, and 15 pa-
tients with extremity tumors.
Most patients (n � 34) received 56Gy in 28 fractions of
2Gy or 25 fractions of 2Gy and 2 fractions with 3Gy. One
patient with a tumor on the head/neck received 54Gy over
30 sessions of 1.8Gy.
Ten patients had no toxicity, 11 patients had grade 1
(mild joint stiﬀness, slight atrophy, and pigmentation
change), 10 patients had grade 2 (patch atrophy, moderate
ﬁbrosis, and moderate joint stiﬀness), and one patient had
grade 3 toxicity (severe joint stiﬀness). For three patients,
insuﬃcient data were available.
Best response to radiotherapy was CR in 4 patients
(11%), PR in 11 patients (31%), and SD in 16 patients (46%).
For 4 patients, no images were available to determine
outcome according to RECIST. CR was documented after
12, 17, 26, and 29 months, and PR was documented after
median 15.5 months (range 4–56 months). During follow-
up, 2 patients developed PD with TTP of 31 and 47 months.
3.3. Systemic Treatment. Nineteen patients received initial
systemic treatment. .is consisted of nonsteroid anti-
inﬂammatory drugs (NSAID) in 10 patients, antihormonal
therapy (HT) in 5 patients, chemotherapy (ChT) in 1 patient,
a tyrosine kinase inhibitor (TKI) in 1 patient, and a combination
of HTand TKI in 1 patient. Details were missing for 1 patient.
Tumor localization was categorized as follows: thoracic/back
in 9 patients, abdominal wall in 7 patients, extremity in 2 pa-
tients, and groin in 1 patient.
Best response during initial systemic treatment was CR for
1 patient (5%), PR for 1 patient (5%), SD for 10 patients (53%),
PD for 2 patients (11%), and unknown for 5 patients (26%).
CR was documented after 12 months, and PR was docu-
mented after 24 months. .e female patient with CR received
HT. .e patient with PR received an NSAID. .e 10 patients
with SD were on NSAIDs (n � 7), HT (n � 2), and TKI
(n � 1). PDwas seen after an NSAID (n � 1) and ChT (n � 1).
During follow-up, 3 patients developed PD with TTP of 6.3,
7.1, and 7.2 months.
After initial systemic treatment, multiple systemic treat-
ments were given to 10 patients in diﬀerent regimens. Seven
patients received 2 treatment regimens and three patients
received a total of 4 treatment regimens.
4. Discussion
.e change in treatment strategies from initial surgery with
or without radiotherapy to initial nonsurgical management
has been fueled by several studies and increasing expertise
about this disease with its unpredictable behavior. .e level
of evidence is limited by the rarity of this disease. .e Dutch
cohort represents a unique and large group of patients with
data on real-life practice. Within this group, analyses show
that a 25% response rate and 52% stable disease rate was
achieved using initial nonsurgical management.
Over the past 20 years, ﬁrst-line nonsurgical management
has increased up to 12.8%. Although the ratio between the
time periodsmight be biased by several factors (such as limited
numbers and registration), the trend towards nonsurgical
management is evident and is expected to increase, as more
specialists adhere to the current guidelines. Although there is
an increase in nonsurgical management, still most patients are
managed by surgery. Complaints such as pain or cosmetic
reasons are reasons to do a resection. A resection could also
have been performed for diagnostic purposes. Finally, limited
experience with nonsurgical treatment in nonreferral centers
could explain this high incidence of surgical excisions. As only
chart review was done for patients with ﬁrst-line nonsurgical
treatment, we can only hypothesize about the reason for
surgical management.
.e literature on ﬁrst-line nonsurgical management is
limited, and most studies are reports from specialized
centers. Retrospective studies with combined data from the
French and Italian research groups reported promising
results for all tumor localizations [23–25]. .e present study
was designed to provide more insight in common practice
for this rare disease on a population-based level. In a na-
tional database of 1134 patients, the number of nonsurgically
treated patients is small, but deﬁnitely increasing. Obviously,
surgery has remained the ﬁrst-line treatment over the last 20
years, but a paradigm shift towards active surveillance can be
observed..e surveillance cohort is the largest group among
patients managed nonsurgically. Radiotherapy was the
second used treatment modality. In general, radiotherapy is
indicated only in serious cases where progression of the
tumor can lead to serious morbidity [6]. .e risk of acute
and late toxicity, including secondary malignancy, restricts
its application, particularly in the young age group and in
those patients with abdominal locations. Compared to the
study by Colombo et al., the current study showed a high
frequency (38%) of patients treated with radiotherapy
compared to 3% in the French/Italian study [23]. No other
studies are available, and the reason for this high number of
primary irradiated tumors is unknown. Compared to the
surveillance cohort, there are a relative high number of
patients with an extremity localization in the radiotherapy
group. Although we do not exactly know, it could be that
patients with an extremity tumor are less likely to be re-
ferred, and when they are referred, they are symptomatic
and therefore prone to have surgery or radiotherapy. .e
small numbers of patients who received systemic treatment
reﬂect the limited evidence for any of the treatment options
and lack of clinical studies in the Netherlands..is study was
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not designed to compare the outcome of the diﬀerent
treatment modalities, merely to report common practice
over the years.
Overall, outcome of ﬁrst-line nonsurgical treatment was
good with a 25% response rate and 52% stable disease rate. Of
all evaluable patients, 90% did not have early progression of
disease. Among patients under active surveillance, 16%
showed spontaneous regression and 57% disease stabilization.
.ese resultsmight be biased because inmany cases, choice for
ﬁrst-line treatment was made after referring the patient to
a tertiary referral center which enabled the physicians to
observe the natural behavior of the tumor, thereby selecting
patients for either active surveillance or more aggressive
treatments. Referring these patients to a tertiary referral center
is common practice in the Netherlands, and so this reﬂects the
common practice in the Netherlands. For radiotherapy, the
patients in the present study received radiotherapy at
the recommended dose of 50–56Gy [6–8, 26]. Results of
radiotherapy showed a response in 43% and SD in 46% of the
patients. During the follow-up period (median of 44 months
(IQR 24–62)), only 2 patients had disease progression with
long TTPs of 31 and 47 months. .ese results are promising
and might seem to advocate radiotherapy. However, radio-
therapy might be considered an aggressive treatment for this
intermediate grade tumor, usually reserved for patients with
advanced disease. Especially in younger patients, given the
low, but present long-term risk on irradiation-induced sar-
comas, radiotherapy is not deemed as ﬁrst-line treatment.
When systemic treatment is chosen, a large variety of possible
agents and regimens are applied (despite the lack of a speciﬁc
registration for DF), such as hormonal agents, NSAIDs,
chemotherapy, and angiogenesis inhibitors, making com-
parison impossible. Although the group in the present study
was small and diverse, results show stabilization and response
in 63% of patients. Again, due to the large variety, no con-
clusions can be made for on preference of speciﬁc agents or
regimens.
Given the lack of randomized studies, treatment de-
cisions should be made during multidisciplinary expert
meetings. Decision making should take into account loca-
tion and growth of the tumor, but in particularly the
symptoms of the patient. A recent study by the French
patients advocacy group SOS desmoid showed that 63% of
patients that participated in a survey reported pain [27].
.e optimal ﬁrst-line nonsurgical management of DF
has been discussed bymany groups, predominantly based on
expert opinions and speciﬁc treatment modalities. .e
European consensus, reported by Kasper et al. [5], advises to
start with active surveillance and switch to active treatment
in case of 3 subsequent reports of progression and that
treatment should be guided by tumor localization. .ere is
no staging system available to predict outcome at the time of
diagnosis. Predictive factors have been described, such as
age, tumor localization, and CTNNB1 mutations [28–33].
Recent data on CTNNB1 mutations show diﬀerent behavior
for tumors with diﬀerent mutations. In the future, these
mutations could play an important rolewhen deciding to initiate
speciﬁc treatment modalities. Moreover, it is increasingly im-
portant to recognize the lack of association between radiological
volume and symptoms [34–36]. Given the chronic condition
and the spontaneous ﬂuctuations of the disease, this should be
taken into account in any decision that will be taken.
By the use of PALGA, the Dutch pathology registry, and
the long study period, we have tried to be as inclusive as
possible. Because referral for a desmoid-type ﬁbromatosis to
one of the sarcoma referral centers is standard practice in the
Netherlands, we consider this overview as unbiased. How-
ever, a part of the patients identiﬁed from PALGA were not
included because they were treated outside the referral
centers. .e referral of these patients is essential to develop
expertise in the treatment of this rare disease.
A limitation of the study is its retrospective nature. As
a result, details on symptoms during or after treatment are
lacking, which could have provided insight into the way
decisions to either management had been taken..erefore,
no comparisons can be made between the diﬀerent
strategies. .e natural behavior of these tumors is vari-
able, varying from spontaneous regression to long-term
disease stabilization and rapid progression. In the ab-
sence of randomization, no clear recommendations can
be given.
5. Conclusion
Desmoid-type ﬁbromatosis remains a rare disease, for which
several treatment modalities are available. Active surveil-
lance seems to be a good and safe initial treatment, with
options for active treatment in case of progression. Im-
portantly, expected beneﬁts from therapy should be well
balanced against potential treatment-induced chronic and
late eﬀects.
Data Availability
Requests for the raw data will be considered by the corre-
sponding author.
Disclosure
.is manuscript was part of the Ph.D. thesis “Tailoring
Desmoid Treatment,” by Danique van Broekhoven, Erasmus
University Rotterdam, March 29, 2017 [37].
Conflicts of Interest
.e authors declare that there are no conﬂicts of interest
regarding the publication of this article.
Authors’ Contributions
Danique L. M. van Broekhoven and Arie J. Verschoor
contributed equally to this work.
Acknowledgments
.e authors would like to thank the PALGA group for
providing them the pathology reports of the patients.
6 Sarcoma
References
[1] C. D. M. Fletcher, J. A. Bridge, P. Hogendoorn, and
F. Mertens,WHO Classiﬁcation of Tumours of Soft Tissue and
Bone, IARC Press, Lyon, France, 4th edition, 2013.
[2] M. Fiore, F. RImareix, L. Mariani et al., “Desmoid-Type
ﬁbromatosis: a front-line conservative approach to select
patients for surgical treatment,” Annals of Surgical Oncology,
vol. 16, no. 9, pp. 2587–2593, 2009.
[3] S. Salas, A. Dufresne, B. Bui et al., “Prognostic factors
inﬂuencing progression-free survival determined from a se-
ries of sporadic desmoid tumors: a wait-and-see policy
according to tumor presentation. Journal of clinical oncol-
ogy,” Journal of Clinical Oncology, vol. 29, no. 26, pp. 3553–
3558, 2011.
[4] D. L. van Broekhoven, D. J. Gru¨nhagen, M. A. den Bakker,
T. van Dalen, and C. Verhoef, “Time trends in the incidence
and treatment of extra-abdominal and abdominal aggressive
ﬁbromatosis: a population-based study,” Annals of Surgical
Oncology, vol. 22, no. 9, pp. 2817–2823, 2015.
[5] B. Kasper, C. Baumgarten, S. Bonvalot et al., “Management of
sporadic desmoid-type ﬁbromatosis: a European consensus
approach based on patients’ and professionals’ expertise–a
sarcoma patients EuroNet and European Organisation for
Research and Treatment of Cancer/Soft Tissue and Bone
Sarcoma Group initiative,” European Journal of Cancer,
vol. 51, no. 2, pp. 127–136, 2015.
[6] R. B. Keus, R. A. Nout, J. Y. Blay et al., “Results of a phase II
pilot study of moderate dose radiotherapy for inoperable
desmoid-type ﬁbromatosis–an EORTC STBSG and ROG
study (EORTC 62991-22998),” Annals of Oncology, vol. 24,
no. 10, pp. 2672–2676, 2013.
[7] R. A. Zlotecki, M. T. Scarborough, C. G. Morris et al., “Ex-
ternal beam radiotherapy for primary and adjuvant man-
agement of aggressive ﬁbromatosis,” International Journal of
Radiation Oncology Biology Physics, vol. 54, no. 1, pp. 177–181,
2002.
[8] B. A. Guadagnolo, G. K. Zagars, and M. T. Ballo, “Long-term
outcomes for desmoid tumors treated with radiation therapy,”
International Journal of Radiation Oncology Biology Physics,
vol. 71, no. 2, pp. 441–447, 2008.
[9] J. Janinis, M. Patriki, L. Vini, G. Aravantinos, and
J. S. Whelan, “.e pharmacological treatment of aggressive
ﬁbromatosis: a systematic review,”Annals of Oncology, vol. 14,
no. 2, pp. 181–190, 2003.
[10] D. Bocale, M. T. Rotelli, A. Cavallini, and D. F. Altomare,
“Anti-oestrogen therapy in the treatment of desmoid tu-
mours. A systematic review,” Colorectal Disease, vol. 13,
no. 12, pp. e388–e395, 2011.
[11] B. Kasper, “Systemic treatment approaches for sporadic
desmoid-type ﬁbromatosis: scarce evidence and recommen-
dations,” Oncology Research and Treatment, vol. 38, no. 5,
pp. 244–248, 2015.
[12] Y. Nishida, S. Tsukushi, Y. Shido, J. Wasa, and N. Ishiguro,
“Successful treatment with meloxicam, a cyclooxygenase-2
inhibitor, of patients with extra-abdominal desmoid tumors:
a pilot study,” Journal of Clinical Oncology, vol. 28, no. 6,
pp. e107–e109, 2010.
[13] A. Hansmann, C. Adolph, T. Vogel, A. Unger, and
G. Moeslein, “High-dose tamoxifen and sulindac as ﬁrst-line
treatment for desmoid tumors,” Cancer, vol. 100, no. 3,
pp. 612–620, 2004.
[14] S. X. Skapek, W. S. Ferguson, L. Granowetter et al., “Vin-
blastine and methotrexate for desmoid ﬁbromatosis in
children: results of a pediatric oncology group phase II trial,”
Journal of Clinical Oncology, vol. 25, no. 5, pp. 501–506, 2007.
[15] N. Penel, A. Le Cesne, B. N. Bui et al., “Imatinib for pro-
gressive and recurrent aggressive ﬁbromatosis (desmoid tu-
mors): an FNCLCC/French Sarcoma Group phase II trial with
a long-term follow-up,” Annals of Oncology, vol. 22, no. 2,
pp. 452–457, 2011.
[16] M. M. Grounder, R. A. Lefkowitz, M. L. Keohan et al.,
“Activity of sorafenib against desmoid tumor/deep ﬁbro-
matoses,” Clinical Cancer Research, vol. 17, no. 12,
pp. 4082–4090, 2011.
[17] D. Garbay, A. Le Cesne, N. Penel et al., “Chemotherapy in
patients with desmoid tumors: a study from the French
Sarcoma Group (FSG),” Annals of Oncology, vol. 23, no. 1,
pp. 182–186, 2012.
[18] I. Mitra, Z. Szucs, M. Libertini et al., “Aggressive ﬁbro-
matosis response to tamoxifen: MRI features with symp-
tomatic correlation–.e Royal Marsden experience,” in
Proceedings of CTOS Annual Meeting, Lisbon, Portugal,
November 2016.
[19] D. L. M. van Broekhoven, D. J. Gru¨nhagen, T. van Dalen et al.,
“Tailored Beta-catenin mutational apporoach in extra-
abdominal sporadic desmoid-type ﬁbromatosis patients
without therapeutic intervention, an Italian and Dutch ini-
tiative,” BMC Cancer, vol. 16, no. 1, 2015.
[20] M. Casparie, A. T. Tiebosch, G. Burger et al., “Pathology
databanking and biobanking in the Netherlands, a central role
for PALGA, the nationwide histopathology and cytopathol-
ogy data network and archive,” Cell Oncology, vol. 29, no. 1,
pp. 19–24, 2007.
[21] E. A. Eisenhauer, P..erasse, J. Bogaerts et al., “New response
evaluation criteria in solid tumours: revised RECISTguideline
(version 1.1),” European Journal of Cancer, vol. 45, no. 2,
pp. 228–247, 2009.
[22] J. C. Cox, J. Stetz, and T. F. Pajak, “Toxicity criteria of the
Radiation .erapy Oncology Group (RTOG) and the Euro-
pean Organization for Research and Treatment of Cancer
(EORTC),” International Journal of Radiation Oncology Bi-
ology Physics, vol. 31, no. 5, pp. 1341–1346, 1995.
[23] C. Colombo, R. Miceli, C. Le Pe´chouw et al., “Sporadic extra-
abdominal wall desmoid-type ﬁbromatosis: surgical resection
can be safely limited to a minority of patients,” European
Journal of Cancer, vol. 51, pp. 186–192, 2015.
[24] S. Bonvalot, N. Terne`s, M. Fiore et al., “Spontaneous re-
gression of primary abdominal wall desmoid tumors: more
common than previously thought,” Annals of Surgical On-
cology, vol. 20, no. 13, pp. 4096–4102, 2013.
[25] N. Penel, A. Le Cesne, S. Bonvalot et al., “Surgical versus non-
surgical approach in primary desmoid-type ﬁbromatosis
patients: a nationwide prospective cohort from the French
Sarcoma Group,” European Journal of Cancer, vol. 83,
pp. 125–131, 2017.
[26] S. Bonvalot, A. Desai, S. Coppola et al., “.e treatment of
desmoid tumors: a stepwise clinical approach,” Annals of
Oncology, vol. 23, no. 10, pp. x158–x166, 2012.
[27] P. Rigaux, D. Lefebvre-Kuntz, and N. Penel, “SOS Desmoı¨de.
Pain burden in desmoid tumor patients: a survey of the
French Advocacy Group SOS Desmoid,” Bull Cancer, vol. 102,
no. 3, pp. 213–216, 2015.
[28] P. Hayry, J. J. Reitamo, S. Totterman, D. Hopfner-Hallikainen,
and A. Sivula, “.e desmoid tumor. II. Analysis of factors
possibly contributing to the etiology and growth behavior,”
American Journal of Clinical Pathology, vol. 77, no. 6,
pp. 674–680, 1982.
Sarcoma 7
[29] A. M. Crago, B. Denton, S. Salas et al., “A prognostic no-
mogram for prediction of recurrence in desmoid ﬁbroma-
tosis,” Annals of Surgery, vol. 258, no. 2, pp. 347–353, 2013.
[30] J. Domont, S. Salas, L. Lacroix et al., “High frequency of beta-
catenin heterozygous mutations in extra-abdominal ﬁbro-
matosis: a potential molecular tool for disease management,”
British Journal of Cancer, vol. 102, no. 6, pp. 1032–1036, 2010.
[31] A. J. Lazar, D. Tuvin, S. Hajibashi et al., “Speciﬁc mutations in
the beta-catenin gene (CTNNB1) correlate with local re-
currence in sporadic desmoid tumors,” American Journal of
Pathology, vol. 173, no. 5, pp. 1518–1527, 2008.
[32] C. Colombo, R. Miceli, A. J. Lazar et al., “CTNNB1 45F mu-
tation is a molecular prognosticator of increased postoperative
primary desmoid tumor recurrence: an independent, multi-
center validation study,”Cancer, vol. 119, no. 20, pp. 3696–3702,
2013.
[33] D. L. van Broekhoven, C. Verhoef, D. J. Grunhagen et al.,
“Prognostic value of CTNNB1 gene mutation in primary
sporadic aggressive ﬁbromatosis,” Annals of Surgical Oncology,
vol. 22, no. 5, pp. 1464–1470, 2015.
[34] N. Kotecki, A. Renaud, M. Ben Hay Amor et al., “Is symptom
worsening associated with RECIST response in demoid tumors
patients?,” in Proceddings CTOS Annual Meeting, Lisbon,
Portugal, November 2016.
[35] J. C. Healy, R. H. Reznek, S. K. Clark, R. K. Phillips, and
P. Armstrong, “MR appearances of desmoid tumors in fa-
milial adenomatous polyposis,” American Journal of Roent-
genology, vol. 169, no. 2, pp. 465–472, 1997.
[36] M. D. Murphey, C. M. Ruble, S. M. Tyszko, A. M. Zbojniewicz,
B. K. Potter, and M. Miettinen, “From the archives of the
AFIP: musculoskeletal ﬁbromatoses-radiologic-pathologic
correlation,” Radiographics, vol. 29, no. 27, pp. 2143–2173,
2009.
[37] D. L. van Broekhoven,Tailoring desmoid treatment, Ph.D. thesis,

















































































Submit your manuscripts at
www.hindawi.com
